Merck flies home to New Jersey after a week of major HIV trial results

Merck flew from Buckingham Airport in Florida to Morristown Municipal Airport on June 11, a 17-minute hop that brought the company's Gulfstream G650ER back to its New Jersey home base. The brief flight followed a longer journey: on June 8, the same aircraft had flown from Morristown to Miami-Opa Locka, suggesting a multi-day trip to the Sunshine State.

The return to Morristown comes the same week Merck announced positive topline results from two Phase 3 trials evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment developed with Gilead. As reported by Merck on June 8, the ISLEND-1 and ISLEND-2 studies met their primary efficacy endpoints, with the regimen proving statistically non-inferior to standard daily therapies. The company also participated in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, where CEO Robert Davis discussed the pipeline's momentum.

Merck's recent flight pattern shows a familiar rhythm: the G650ER made a round trip to Florida over two days, then returned home. For a company whose CEO is actively touting a "transformation" in its pipeline, the week's news—and the flights that bookended it—underscore a business that moves as fast as its aircraft.